Get the Stockscreener App
76.90
0.81%
-0.63
After Hours:
76.12
-0.78
-1.01%
Halozyme Therapeutics Inc stock is traded at $76.90, with a volume of 1.12M.
It is down -0.81% in the last 24 hours and up +20.08% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$77.53
Open:
$77.04
24h Volume:
1.12M
Relative Volume:
0.52
Market Cap:
$8.99M
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
25.46
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+2.63%
1M Performance:
+20.08%
6M Performance:
+26.29%
1Y Performance:
+27.02%
1-Day Range:
$76.51
$77.59
1-Week Range:
$74.22
$77.59
52-Week Range:
$42.01
$77.59
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
76.90 | 8.87B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-10-25 | Resumed | Goldman | Neutral |
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Jacobs Levy Equity Management Inc. Makes New $11.64 Million Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Sets New 1-Year HighTime to Buy? - MarketBeat
United Services Automobile Association Acquires New Shares in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics stock hits all-time high at 76.34 USD - Investing.com
Halozyme Therapeutics stock hits all-time high at 76.34 USD By Investing.com - Investing.com Nigeria
Great Lakes Advisors LLC Purchases 98,190 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. $HALO Shares Bought by Panoramic Capital LLC - MarketBeat
Halozyme Therapeutics, Inc. $HALO Shares Bought by Clark Capital Management Group Inc. - MarketBeat
Redwood Investments LLC Has $2.57 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Teza Capital Management LLC Buys New Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics, Inc. $HALO Holdings Lifted by Hancock Whitney Corp - MarketBeat
EFG Asset Management North America Corp. Has $6.57 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Cutter Capital Management LP Purchases New Shares in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Does Halozyme Stock Offer More Potential After Its Recent Strong Price Run in 2025? - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion - sharewise.com
Price Channel Expanding on Halozyme Therapeutics Inc.’s ChartVolume Spike & AI Powered Market Trend Analysis - beatles.ru
Canada Pension Plan Investment Board Lowers Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Reaches New 1-Year HighStill a Buy? - MarketBeat
Halozyme Therapeutics Inc. stock prediction for this weekWeekly Trade Summary & Real-Time Buy Signal Notifications - Newser
RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer - GlobeNewswire Inc.
Pinnacle Wealth Planning Services Inc. Purchases New Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
What drives Halozyme Therapeutics Inc.’s stock priceJuly 2025 Price Swings & Stepwise Trade Signal Guides - خودرو بانک
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings - sharewise.com
What to do if you’re stuck in Halozyme Therapeutics Inc.Market Rally & Smart Investment Allocation Tips - Newser
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns - Yahoo Finance
Forecasting Halozyme Therapeutics Inc. price range with options dataDividend Hike & Weekly High Return Stock Forecasts - Newser
Steamboat Capital Partners LLC Sells 99,751 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Is Halozyme Therapeutics Inc. stock entering bullish territory2025 Market WrapUp & Safe Capital Growth Tips - Newser
Halozyme Therapeutics Inc. stock chart pattern explainedLong Setup & Technical Entry and Exit Alerts - Newser
Applying Wyckoff theory to Halozyme Therapeutics Inc. stockMarket Volume Report & Accurate Intraday Trade Tips - Newser
Halozyme Therapeutics Inc. recovery potential after sell off2025 Key Lessons & Weekly Top Stock Performers List - Newser
Halozyme Therapeutics CEO Torley sells $4.44 million in stock By Investing.com - Investing.com Canada
Halozyme at Wells Fargo Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Halozyme Therapeutics (HALO): Revolutionizing Drug Delivery and Scaling Commercial Success - AInvest
Halozyme Therapeutics Presents at Wells Fargo 20th Annual Healthcare Conference 2025: Q&A Session with Helen Torley - AInvest
Halozyme up after guidance raise, Morgan Stanley upgrade - MSN
Transcript : Halozyme Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-04-2025 01 - MarketScreener
4 PEG-Rated GARP Stocks That Offer Both Value and Growth - Zacks Investment Research
Halozyme Therapeutics stock reaches all-time high at 74.79 USD By Investing.com - Investing.com Australia
Rafferty Asset Management LLC Cuts Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Leading vs lagging indicators on Halozyme Therapeutics Inc. performance2025 Earnings Surprises & AI Powered Buy and Sell Recommendations - Newser
Will Halozyme Therapeutics Inc. outperform the marketQuarterly Trade Summary & Free Safe Entry Trade Signal Reports - Newser
What to expect from Halozyme Therapeutics Inc. in the next 30 daysPortfolio Gains Summary & Free Community Supported Trade Ideas - Newser
Trend analysis for Halozyme Therapeutics Inc. this weekJuly 2025 Technicals & Safe Capital Growth Plans - Newser
Visual trend scoring systems applied to Halozyme Therapeutics Inc.Weekly Stock Summary & Long-Term Growth Stock Strategies - Newser
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice - sharewise.com
Connaughton sells Halozyme Therapeutics (HALO) stock worth $294,736 By Investing.com - Investing.com Australia
Halozyme Therapeutics (HALO)A Momentum Leader with Strong Performance - AInvest
Halozyme Therapeutics stock reaches all-time high at 74.79 USD - Investing.com
Halozyme Therapeutics and atai Life Sciences N.V. Lead Medical Stocks with 53.4% and 245.1% Year-to-Date Returns Respectively. - AInvest
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):